compound 20

amide bond between Phe-Gly of tripeptide replaced with ketomethylene; structure given in first source

Also Known As:

(5S-5-benzamido-4-oxo-6-phenylhexanoyl-L-proline); Bz-Phe-Gly-Pro, ketomethylene analog; SRI 20; SRI-20; ketoACE; L-Proline, 1-(5-(benzoylamino)-1,4-dioxo-6-phenylhexyl)-, (S)-

Networked: 66 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - compound 20: 66

Experts

1.	Huang, Wenlong: 2 articles (04/2022 - 09/2017)
2.	Qian, Hai: 2 articles (04/2022 - 09/2017)
3.	Qiu, Qianqian: 2 articles (04/2022 - 09/2017)
4.	Shi, Wei: 2 articles (04/2022 - 09/2017)
5.	Li, Yan: 2 articles (08/2020 - 07/2010)
6.	Largent-Milnes, Tally M: 2 articles (01/2020 - 09/2015)
7.	Mishra, Rama K: 2 articles (10/2017 - 01/2010)
8.	Chen, Xuanzhen: 1 article (08/2022)
9.	Liu, Junyi: 1 article (08/2022)
10.	Shi, Xueqi: 1 article (08/2022)

Related Diseases

1.	Necrosis 02/18/2022 - "In this study, we used our recently described exercised mdx (ex mdx) mouse model characterised by accelerated heart pathology, and the specific PKCθ inhibitor Compound 20 (C20), to show that inhibition of this kinase leads to a significant reduction in the number of immune cells infiltrating the heart, as well as necrosis and fibrosis. "
2.	Fibrosis (Cirrhosis) 02/18/2022 - "In this study, we used our recently described exercised mdx (ex mdx) mouse model characterised by accelerated heart pathology, and the specific PKCθ inhibitor Compound 20 (C20), to show that inhibition of this kinase leads to a significant reduction in the number of immune cells infiltrating the heart, as well as necrosis and fibrosis. "
3.	Acute Pain 09/15/2015 - "Compound 20 was not significantly effective in alleviating acute pain. "
4.	Toxoplasmosis 01/01/2018 - "Importantly, the possibility of targeting the encysted, bradyzoite, form of the parasite with AbA and Compound 20 was demonstrated, indicating that this class of compounds may provide the basis for the first effective treatment for chronic toxoplasmosis."
5.	Neoplasms (Cancer) 01/01/2019 - "Compound 20 may be used as a potential lead molecule for cancer studies." 01/01/2023 - "Thus compound 11 exhibited cytotoxic activity with IC50 8.58 μM, 9.22 μM and 7.53 μM, compound 20 showed IC50 9.99 μM, 6.72 μM and 6.87 μM, analogue 21 displayed IC50 10.80 μM, 7.90 μM and 9.16 μM, compound 23 showed IC50 4.82 μM, 11.05 μM and 4.42 μM and derivative 24 exhibited potent cytotoxic activity with IC50 7.44 μM, 5.18 μM and 8.22 μM against HepG-2, HCT-116, and MCF-7 cancer cell lines, respectively. " 10/06/2022 - "In addition, compound 20 shows high anti-proliferative effects on MV-4-11 and MDA-MB-468 tumor cells and low cytotoxicity on AML-12 hepatocytes. " 08/05/2022 - "A pyrrolidin-1-yl derivative, compound 20, exhibited strong antiproliferative activities (average IC50 = 13.4 nM) against four cancer cell lines. " 04/15/2022 - "Furthermore, compound 20 inhibited the growth of tumor cell xenografts in vivo, and prolonged the survival of the tumor-bearing mice."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Glucose (Dextrose)
3.	Interleukin-17 (Interleukin 17)
4.	Silymarin
5.	RNA (Ribonucleic Acid)
6.	Alloxan
7.	Interleukin-22 (IL-22)
8.	Imiquimod (Aldara)
9.	Cytostatic Agents
10.	Caspase 3 (Caspase-3)

Related Therapies and Procedures

1.	Ligation
2.	Therapeutics
3.	Contraception (Birth Control)
4.	Oral Administration